French Industry Network
SEE OTHER BRANDS

The latest industries and services news from France

French Industry Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Industry Network.

Press releases published on May 23, 2025

TravelingWiki CEO Jonathan Sutter Named Among Top Global Duke Alumni Leaders (Alongside Tim Cook, Melinda Gates, Nixon)

TravelingWiki CEO Jonathan Sutter Named Among Top Global Duke Alumni Leaders (Alongside Tim Cook, Melinda Gates, Nixon)

Jonathan Sutter named by Microsoft's Bing alongside Tim Cook, Melinda French Gates and Richard Nixon as "most successful (Duke) alumni" DALLAS, TX, UNITED STATES, May 23, 2025 /⁨EINPresswire.com⁩/ -- Leading into the Memorial Day Holiday Weekend where …

First report on world’s animal health reveals changing spread of disease impacting food security, trade and ecosystems

First report on world’s animal health reveals changing spread of disease impacting food security, trade and ecosystems

Inaugural State of the World’s Animal Health report finds several animal diseases reaching new areas, with half of those reported able to jump to people PARIS, FRANCE, May 23, 2025 /⁨EINPresswire.com⁩/ -- Infectious animal diseases are affecting new areas …

Assystem: Combined General Meeting of 23 May 2025 - Voting results and dividend for financial year 2024

Assystem: Combined General Meeting of 23 May 2025 - Voting results and dividend for financial year 2024

Combined General Meeting of 23 May 2025 Voting results and dividend for financial year 2024 Paris-La Défense, on 23 May 2025, 6.00 p.m (CET) – Assystem S.A. (ISIN: FR0000074148 – ASY), confirms that its Combined General Meeting was held today, at the …

Assystem : Assemblée Générale Mixte du 23 mai 2025 - Résultat des votes et dividende au titre de l'exercice 2024

Assystem : Assemblée Générale Mixte du 23 mai 2025 - Résultat des votes et dividende au titre de l'exercice 2024

Assemblée Générale Mixte du 23 mai 2025 Résultat des votes et dividende au titre de l’exercice 2024 Paris-La Défense, le 23 mai 2025, 18h00 – L’Assemblée Générale Mixte d’Assystem S.A.(ISIN : FR0000074148 – ASY) s’est réunie ce jour au centre de …

Combined General Meeting of June 13, 2025

Combined General Meeting of June 13, 2025

       Combined General Meeting of June 13, 2025 Access to information Paris, France – May 23, 2025 – Atos SE shareholders are invited to attend the Combined General Meeting of the Company to be held on Friday, June 13, 2025 at 10 a.m. (Paris time) at the …

Assemblée Générale Mixte du 13 juin 2025

Assemblée Générale Mixte du 13 juin 2025

Assemblée Générale Mixte du 13 juin 2025 Modalités de mise à disposition des documents préparatoires Paris, France – 23 mai 2025 – Les actionnaires d’Atos SE sont invités à participer à l’Assemblée Générale mixte de la Société qui se tiendra le vendredi 13 …

Voting Results from Constellium's 2025 Annual General Meeting

Voting Results from Constellium's 2025 Annual General Meeting

PARIS, May 23, 2025 (GLOBE NEWSWIRE) -- Constellium SE (NYSE: CSTM) announced today that the voting results for its Annual General Meeting of Shareholders held on May 15, 2025 (the “AGM”) have been published on the Company’s website (https://www. …

Inventiva reports 2025 First Quarter Financial Information¹

Inventiva reports 2025 First Quarter Financial Information¹

Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral …

Inventiva publie ses informations financières¹ du 1er trimestre 2025

Inventiva publie ses informations financières¹ du 1er trimestre 2025

Trésorerie et équivalents de trésorerie à 67,9 millions d’euros Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans …

EXEL Industries: 2024–2025 half-year results

EXEL Industries: 2024–2025 half-year results

First half 2024–2025 results Priority given to reducing debt and optimizing WCR in the first half, positive net income driven by lower costs in response to lower volumes in Agricultural Spraying In the first half of 2024–2025, EXEL Industries's revenue …

EXEL Industries : résultats semestriels 2024–2025

EXEL Industries : résultats semestriels 2024–2025

Résultats semestriels 2024–2025 Priorité à la réduction de la dette et l’optimisation du BFR au premier semestre, résultat net positif porté par la baisse des coûts en réaction à la baisse des volumes dans la Pulvérisation agricole Au premier semestre 2024 …

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic …

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025

Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI 765063 in combination with programmed …

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours sur la modulation de l’immunité innée et l’activité antitumorale via le blocage de SIRPα à l’ASCO 2025 BI …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service